Thromb Haemost 2018; 118(12): 2014-2017
DOI: 10.1055/s-0038-1676074
Invited Editorial Focus
Georg Thieme Verlag KG Stuttgart · New York

Optimizing Stroke and Bleeding Risk Assessment in Patients with Atrial Fibrillation: A Balance of Evidence, Practicality and Precision

Marco Proietti
1  Istituto di Ricerche Farmacologiche “Mario Negri” IRCCS, Milan, Italy
2  Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy
,
Nebojsa Mujovic
3  School of Medicine, University of Belgrade, Belgrade, Serbia
4  Cardiology Clinic, Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia
,
Tatjana S. Potpara
3  School of Medicine, University of Belgrade, Belgrade, Serbia
4  Cardiology Clinic, Clinical Centre of Serbia, University of Belgrade, Belgrade, Serbia
› Author Affiliations
Further Information

Publication History

31 October 2018

31 October 2018

Publication Date:
20 November 2018 (eFirst)

Optimal stroke prevention using oral anticoagulant (OAC) therapy is essential for the management of patients with atrial fibrillation (AF) who are at increased risk of stroke, but decision making on thromboprophylaxis requires evaluation of individual patient's thromboembolic and bleeding risks.[1] Several risk assessment tools have been developed to streamline the evaluation of patients with AF but navigating through the labyrinth of options may be confusing for clinicians.[2]